Clinical Trial Update: A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing subcutaneous Mircera to darbepoetin alfa for maintenance treatment of anemia in kidney transplant recipients; the study is completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2016-08-05